



Antibiotice



Explanatory material regarding items 2.a. and 3. of the Notice of the Extraordinary General Meeting of Shareholders dated 29/30.04.2026

2.a. Approval of the increase of the amounts of the following credit facilities, as follows: Increase of the amount of the Global Working Capital Facility granted by Transilvania Bank SA, with a new maturity date, i.e. 30.06.2027, by the amount of 19,300,000 Ron, from 45,700,000 Ron to 65,000,000 Ron; the establishment of guarantees in favor of Transilvania Bank SA, namely a movable mortgage over present and future receivables, as well as over the balances of current accounts and sub-accounts opened by SC ANTIBIOTICE SA with Transilvania Bank SA to be registered with the National Registry for Movable Property Publicity (RNPM); and the appointment of Mr. Ioan NANI, in his capacity as General Director of Antibiotice SA, to negotiate/agree and sign the credit documentation (the credit agreement, security agreements, as well as any other necessary applications, forms or declarations). Accordingly, all financing documents signed/to be signed by the authorized person for the implementation of this resolution shall be assumed by SC Antibiotice SA.

3. Approval of the increase of the multi-currency, multi-product credit facility (cash and non-cash) granted by UniCredit Bank from 15,000,000 RON to 15,000,000 RON.

On 01.01.2026, Antibiotice S.A. had approved by the General Meeting of Shareholders and contracted the following working capital loans:

- operational financing line in the form of a “Global Revolving Working Capital Facility, multi-currency, with usage in RON, EUR, and USD,” with a total amount of 35,000,000 lei with Transilvania Bank;
- short-term loan for operational payments, with a total amount of 15,000,000 Euro with Transilvania Bank, whose maturity date is 15.05.2026;
- operational financing line in the form of a “Global Revolving Working Capital Facility, multi-currency, with usage in RON, EUR, and USD,” with a total amount of 15,000,000 lei with UniCredit Bank.

In order to preserve the company’s financial stability and ability to fulfill current its obligations, Antibiotice S.A. utilizes working capital financing facilities, which are correlated with the volume of activity, continuously aiming to maintain an optimal level of financial equilibrium indicators.

Based on the analysis of estimated cash inflows and outflows for 2026, considering an improvement in receivables collection and inventory turnover, Antibiotice records periods during which cash inflows do not cover operational expense.



Antibiotice



Thus, the need arises:

- to increase the “Global Working Capital Facility” with Transilvania Bank SA from 45,700,000 lei (a value approved in the meeting of the Management Board held on 27.02.2026) to 65,000,000 lei;
- to convert the short-term loan for operational payments, with a total amount of 15,000,000 Euro, contracted with Transilvania Bank, with a maturity date of 15.05.2026 into an operational financing line by increasing the multi-currency, multi-product, cash and non-cash credit facility contracted with UniCredit Bank from the amount of 15,000,000 RON to 91,500,000 RON.

The use of operational credit facilities will take place when there is a gap between collections and operational payments, on a revolving basis.

This measure aims to clearly separate the sources of financing for operational activities and investments.

The economic and financial indicators confirm a balanced financial structure, complying with safety thresholds regarding liquidity, solvency, and debt ratio - its level increases to an acceptable level for a company undertaking significant investments in production infrastructure within a short period of time.

General Director,
Nani Ioan, Economist

Financial Director,
Coman Paula, Economist